相关实验视频

Updated: Jun 11, 2025

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

关于SUDEP的最新审查:风险评估,背景和探测设备

C P J A Monté¹, J B A M Arends², R H C Lazeron³

¹Academic Center for Epileptology Kempenhaeghe, Heeze, The Netherlands; Private Practice of Neurology, Zottegem, Belgium.

Epilepsy & behavior : E&B

|October 9, 2024

概括

中突然意外死亡 (SUDEP) 与泛性强力克隆性 (GTC) 有关. 风险评分和探测器 (SDD) 可能有助于预防,但需要进一步验证.

科学领域:

神经学神经学
发病学 (Epileptology) 是一个专业的学科.
医疗器械技术医疗器械技术

背景情况:

中突然意外死亡 (SUDEP) 仍然是患者护理的一个关键问题.
综合性强力-克隆性发作 (GTC) 被确定为SUDEP的主要危险因素.
现有的SUDEP风险分层工具,包括评分系统,需要在一般患者群体中进一步验证.

研究的目的:

审查关于SUDEP的当前知识,重点关注风险因素,评分系统,拟议的机制和检测设备 (SDD).
评估SUDEP风险分层的实用性和SDD在SUDEP预防策略中的潜力.
讨论关于SUDEP的潜在机制的假设.

主要方法:

关于SUDEP风险因素,评分系统 (SUDEP-7,SUDEP-3,SUDEP-CARE,Kempenhaeghe) 的文献综述,建议的机制,以及验证的探测器 (SDD).
对将GTC频率与SUDEP风险联系起来的流行病学数据的分析.
对选定的SDD的验证状态和性能指标的评估.

主要成果:

综合性强力-克隆性 (GTC) 与SUDEP有很强的关联,报告的几率比率很高.
现有四个SUDEP风险评分系统,其中三个已在不同程度上得到验证,但没有一个得到广泛临床使用的充分验证.
五种SDD (发作链接®,Epi-Care®,NightWatch,Empatica,Nelli®) 在检测强力-克隆性发作 (TC) 方面显示出高灵敏度 (>90%),尽管直接预防SUDEP尚未得到证实.

结论:

虽然GTC频率是一个关键的SUDEP风险因素,并且SDD显示出对夜间监督的希望,但仍需要对SUDEP预防进行强有力的验证.
目前的SUDEP风险评分系统提供了一个框架,但缺乏普遍验证.
进一步研究SUDEP机制和SDD的临床实用性对于改善患者的治疗结果至关重要.

关键词:

在 SUDEP 里面,你会发现 SUDEP 的风险因素 SUDEP风险评分系统的风险评分系统.一般化的强力克隆性发作.这就是SUDEP的机制.扣押检测设备的扣押检测设备.

更多相关视频

$Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note$ 05:54

Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note

Published on: June 13, 2016

Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits

Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits

Published on: March 27, 2021

相关概念视频

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Seizures: Classification

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:

Arteries of the Lower Limbs

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...